Y
Yung-mae Yao
Researcher at Novartis
Publications - 13
Citations - 1347
Yung-mae Yao is an academic researcher from Novartis. The author has contributed to research in topics: Panobinostat & Cancer. The author has an hindex of 8, co-authored 11 publications receiving 1242 citations.
Papers
More filters
Journal ArticleDOI
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
Susan Wee,Zainab Jagani,Kay Xiaoqin Xiang,Alice Loo,Marion Dorsch,Yung-mae Yao,William R. Sellers,Christoph Lengauer,Frank Stegmeier +8 more
TL;DR: This study provides molecular insights that help explain the heterogeneous response of KRAS mutant cancers to MEK pathway inhibition and presents a strong rationale for the clinical testing of combination MEK and PI3K targeted therapies.
Journal ArticleDOI
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan,Xu Wu,Jiqing Jiang,Wenqi Gao,Yongqin Wan,Dai Cheng,Dong Han,Jun Liu,Nathan P. Englund,Yan Wang,Stefan Peukert,Karen Miller-Moslin,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Yun Jiang,Jeffrey Tsao,Fangxian Sun,AnneMarie Culazzo Pferdekamper,Stephanie Kay Dodd,Tove Tuntland,Wieslawa Maniara,Joseph Kelleher,Yung-mae Yao,Markus Warmuth,Juliet Williams,Marion Dorsch +27 more
TL;DR: Structural-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl- 3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.
Journal ArticleDOI
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies
Seth Ettenberg,Olga Charlat,Michael P. Daley,Shanming Liu,Karen Vincent,Darrin Stuart,Alwin Schuller,Jing Yuan,Beatriz Ospina,J. E. F. Green,Qunyan Yu,Renee Walsh,Sharon Li,Rita Schmitz,Holger Heine,Sanela Bilic,Lance Ostrom,Rebecca A. Mosher,K. Felix Hartlepp,Zhenping Zhu,Stephen E. Fawell,Yung-mae Yao,David Raymond Stover,Peter Finan,Jeffery A. Porter,William R. Sellers,Ingo Klagge,Feng Cong +27 more
TL;DR: These studies provide insights into Wnt-induced LRP5/6 activation and show the potential utility of LRP6 antibodies in WNT-driven cancer.
Journal ArticleDOI
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio,David Vilanova,Peter Atadja,Patricia Maiso,Edvan de Queiroz Crusoe,Diego Fernández-Lázaro,Mercedes Garayoa,Laura San-Segundo,Teresa Hernández-Iglesias,Enrique de Alava,Wenlin Shao,Yung-mae Yao,Atanasio Pandiella,Jesús F. San-Miguel +13 more
TL;DR: The addition of panobinostat to dexamethasone and either bortezomib or lenalidomide plus steroids resulted in clear potentiation in multiple myeloma cell lines, freshly isolated plasma cells, and murine models of multipleMyeloma.
Journal ArticleDOI
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/β-catenin signaling
Alix Scholer-Dahirel,Michael R. Schlabach,Alice Loo,Linda Bagdasarian,Ronald Meyer,Ribo Guo,Steve Woolfenden,Kristine Yu,Judit Markovits,Karen Killary,Dmitry Sonkin,Yung-mae Yao,Markus Warmuth,William R. Sellers,Robert A. Schlegel,Frank Stegmeier,Rebecca Mosher,Margaret McLaughlin +17 more
TL;DR: It is shown that active Wnt/β-catenin signaling is required for maintenance of colorectal tumor xenografts harboring APC mutations and this results support efforts to treat human coloreCTal cancer by pharmacological inhibition of the Wnt /β- catenin pathway.